shortage of glp-1 receptor agonists Government declares 'national shortage' for type 2 diabetes until 2024 GLP-1 Receptor Agonist Market Size
Description
Front Endocrinol (Lausanne) 9
the Take-Away A new class of diabetes and weight-loss drugs is drawing attention from researchers, and the early data on opioid addiction may be the most compelling signal yet
Back Patchen, T (8 March 2024) 'FDA approves novo's obesity drug Wegovy to reduce cardiovascular events', Biospace
515,516,517 GLP-1 may improve the livers antioxidant capacity and metabolic function by activating Sirt1, thereby helping to alleviate the pathological changes associated with NASH
The drugs have been credited with reshaping not only individual health but also corporate strategies, food industry investments, and public health discussions about obesity as a chronic disease requiring medical treatment
Parasite antigen in serum predicts the presence of viable brain parasites in patients with apparently calcified cysticercosis only
